A detailed history of Glenmede Trust CO Na transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Glenmede Trust CO Na holds 10,261 shares of NBIX stock, worth $1.29 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,261
Previous 11,089 7.47%
Holding current value
$1.29 Million
Previous $1.53 Million 22.61%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $94,872 - $126,808
-828 Reduced 7.47%
10,261 $1.18 Million
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $243,661 - $266,619
-1,862 Reduced 14.38%
11,089 $1.53 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $26,340 - $29,035
-202 Reduced 1.54%
12,951 $1.79 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $1.07 Million - $1.34 Million
10,127 Added 334.67%
13,153 $1.73 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $586,496 - $730,469
-6,238 Reduced 67.34%
3,026 $340,000
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $711,377 - $929,908
-7,559 Reduced 44.93%
9,264 $937,000
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $696,348 - $829,066
6,525 Added 63.36%
16,823 $2.01 Million
Q3 2022

Nov 16, 2022

SELL
$92.03 - $107.81 $438,522 - $513,714
-4,765 Reduced 31.63%
10,298 $1.09 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $132,632 - $175,122
-1,750 Reduced 10.41%
15,063 $1.47 Million
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $347,760 - $455,088
-4,800 Reduced 22.21%
16,813 $1.58 Million
Q4 2021

Feb 15, 2022

SELL
$79.65 - $106.22 $817,925 - $1.09 Million
-10,269 Reduced 32.21%
21,613 $1.84 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $297,407 - $341,752
-3,451 Reduced 9.77%
31,882 $3.06 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $47,308 - $54,100
-529 Reduced 1.48%
35,333 $3.44 Million
Q1 2021

May 18, 2021

SELL
$87.57 - $119.4 $414,556 - $565,239
-4,734 Reduced 11.66%
35,862 $3.49 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $1.51 Million - $1.88 Million
17,363 Added 74.73%
40,596 $3.89 Million
Q3 2020

Nov 16, 2020

SELL
$96.16 - $135.15 $288,480 - $405,450
-3,000 Reduced 11.44%
23,233 $2.23 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $593,162 - $908,739
6,971 Added 36.19%
26,233 $3.2 Million
Q4 2019

Feb 12, 2020

BUY
$86.8 - $118.57 $92,528 - $126,395
1,066 Added 5.86%
19,262 $2.07 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $744,656 - $901,726
8,884 Added 95.4%
18,196 $1.64 Million
Q2 2019

Aug 13, 2019

SELL
$72.24 - $91.27 $722 - $912
-10 Reduced 0.11%
9,312 $786,000
Q1 2019

May 14, 2019

SELL
$69.31 - $91.53 $693 - $915
-10 Reduced 0.11%
9,322 $821,000
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $7,651 - $13,928
112 Added 1.21%
9,332 $666,000
Q3 2018

Nov 15, 2018

SELL
$98.88 - $125.85 $791 - $1,006
-8 Reduced 0.09%
9,220 $1.13 Million
Q2 2018

Aug 15, 2018

SELL
$75.3 - $105.99 $96,384 - $135,667
-1,280 Reduced 12.18%
9,228 $907,000
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $504,068 - $643,930
10,508
10,508 $0

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Glenmede Trust CO Na Portfolio

Follow Glenmede Trust CO Na and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.